Document Detail


Approaches to the treatment of chronic myeloid leukemia.
MedLine Citation:
PMID:  7919235     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
In the past two decades there have been a number of advances in the treatment of chronic myeloid leukemia (CML) in chronic phase. There has been very little progress in the management of advanced disease. Hydroxyurea and interferon-alpha have replaced busulfan as first-line therapy in chronic phase. Hydroxyurea provides excellent control of the disease for periods of months or years and has little toxicity. Interferon-alpha induces a reduction in the Philadelphia chromosome in a substantial minority of patients. Interferon-alpha may also prolong survival. Neither hydroxyurea nor interferon-alpha is able to cure the disease. Patients in chronic phase may be cured by allogeneic bone marrow transplantation (BMT). This procedure has a number of limitations, however, including limited availability, high cost, and substantial morbidity and mortality. Current challenges in BMT are to increase its applicability, to reduce graft-versus-host disease, and to augment graft-versus-leukemia effects. The role of autologous transplantation in CML remains speculative.
Authors:
D G Savage; J M Goldman
Related Documents :
11801465 - Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoi...
15224365 - Membranous glomerulonephritis in chronic lymphocytic leukemia.
3541875 - The impact of leukemia status at the time of hla-identical sibling marrow transplantati...
10914055 - Medical management of aspergillus flavus endocarditis.
16941165 - Renal failure in septic shock: predictive value of doppler-based renal arterial resisti...
15520055 - Higher mortality after allogeneic peripheral-blood transplantation compared with bone m...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  International journal of hematology     Volume:  60     ISSN:  0925-5710     ISO Abbreviation:  Int. J. Hematol.     Publication Date:  1994 Jul 
Date Detail:
Created Date:  1994-11-09     Completed Date:  1994-11-09     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9111627     Medline TA:  Int J Hematol     Country:  IRELAND    
Other Details:
Languages:  eng     Pagination:  1-21     Citation Subset:  IM    
Affiliation:
LRF Centre for Adult Leukaemia, Royal Postgraduate Medical School, London, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Bone Marrow Transplantation
Busulfan / therapeutic use
Hydroxyurea / therapeutic use
Interferon-alpha / therapeutic use
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy*
Chemical
Reg. No./Substance:
0/Interferon-alpha; 127-07-1/Hydroxyurea; 55-98-1/Busulfan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Growth factor receptors, phospholipases, phospholipid kinases and actin reorganization.
Next Document:  Red cell membrane disorders in the Japanese population: clinical, biochemical, electron microscopic,...